Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab as Neoadjuvant Treatment in HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03337841
Recruitment Status : Unknown
Verified November 2017 by Masatoshi Kudo, Kindai University.
Recruitment status was:  Not yet recruiting
First Posted : November 9, 2017
Last Update Posted : November 9, 2017
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Masatoshi Kudo, Kindai University

Brief Summary:
The aim of this study is to elucidate the utility of the immune checkpoint inhibitor pembrolizumab in preventing the recurrence of HCC when administered before and after curative surgery or ablation.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Pembrolizumab Phase 2

Detailed Description:
Each subject will participate in the trial from the time he or she signs the informed consent form until the final contact. After a screening phase of up to 28 days, each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.) Subjects who discontinue for reasons other than tumor recurrence will have post-treatment follow-up visits for monitoring disease status until tumor recurrence, until initiation of non-study cancer treatment, until withdrawal of consent for study participation, or until becoming lost to follow-up. All subjects will be followed for overall survival until death, withdrawal of consent for study participation, or the end of the study, whichever comes first. After the end of trial treatment, each subject will be followed for 30 days for adverse event monitoring. Serious adverse events will be collected for 90 days after the end of treatment or for 30 days after the end of treatment if the subject initiates new anticancer therapy, whichever is earlier.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Neoadjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma With Pembrolizumab Trial (AURORA)
Estimated Study Start Date : November 10, 2017
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pembrolizumab
Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
Drug: Pembrolizumab
Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
Other Names:
  • MK-3475
  • Keytruda




Primary Outcome Measures :
  1. One-year recurrence-free survival rate [ Time Frame: 1 year after curative treatment ]
    One-year recurrence-free survival rate is defined as the recurrence-free survival rate 1year after curative treatment.


Secondary Outcome Measures :
  1. Recurrence free survival [ Time Frame: From the date of enrollment until the date of first recurrence or date of death from any cause, whichever came first, up to 72 weeks. ]
    Recurrence-free survival is defined as the length of time from the date of confirmation of complete cure to the earliest of the following: the date when recurrence is diagnosed or the date of death due to any cause.

  2. Overall survival [ Time Frame: From date of enrollment until the date of death from any cause, up to 72 weeks. ]
    Overall survival is defined as the length of time from the date of confirmation of complete cure to the date of death due to any cause.

  3. Objective response rate after neoadjuvant phase [ Time Frame: Evaluation period is just before curative treatment, up to 4 weeks. ]
    Tumor assessment in accordance with RECIST1.1 will be performed after neoadjuvant administration.

  4. Tumor markers [ Time Frame: From the date of enrollment until the date of last administration of study drug, up to 72 weeks. ]
    Baseline levels of tumor markers including AFP, AFP-L3, and PIVKA-II and changes in their levels will be exploratory investigated in relation to the therapy efficacy.

  5. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: From the date of enrollment until the date of last administration of study drug, thereafter up to 4 months ]
    The safety endpoints of this study are the safety of pembrolizumab as neoadjuvant and/or adjuvant therapy in patients with HCC. To determine the safety of the drug, the degree of toxicity is evaluated in accordance with the CTCAE (version 4.0).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hepatocellular carcinoma for which radical cure is possible by resection or RFA.
  • Diagnosed with typical HCC based on imaging findings with Intermediate or High Risk of recurrence as assessed by tumor characteristics.
  • Male or female subjects >/= 20 years of age
  • Child-Pugh score A
  • ECOG Performance Status of 0.
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Recurrent HCC
  • HCC with extrahepatic metastasis and/or vascular invasion confirmed by diagnostic imaging
  • Subjects with poorly controlled ascites (excluding cases that responded to diuretic therapy)
  • Subjects with hepatic encephalopathy
  • Past history of immunotherapy
  • Past history or complication of an active autoimmune disorder.
  • Past history or complication of interstitial pneumonia.
  • Past or current history of malignant tumor, except for curative cases
  • Subjects with renal insufficiency requiring hemodialysis or peritoneal dialysis.
  • Past or current history of severe cardiovascular disease
  • Active clinically serious infections except for HBV or HCV
  • Subjects with convulsive disorder requiring treatment (risk of convulsive seizures).
  • Subjects with gastrointestinal bleeding causing clinical problems within a 4-week period before enrollment in this study.
  • Subjects with thrombosis or embolism that developed within a 6-month period before enrollment in this study
  • Subjects with pregnant or breast feeding, or planning to become a parent
  • Subjects with possible allergic reaction to the investigational drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03337841


Contacts
Layout table for location contacts
Contact: Kazuomi Ueshima, Lecturer +81-72-366-0221 ext 3525 kaz-ues@med.kindai.ac.jp
Contact: Masatoshi Kudo, Professor +81-72-366-0221 ext 3149 m-kudo@med.kindai.ac.jp

Sponsors and Collaborators
Kindai University
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Masatoshi Kudo, Professor Kindai University Faculty of Medicine, Gastroenterology and Hepatology
Layout table for additonal information
Responsible Party: Masatoshi Kudo, Professor, Kindai University
ClinicalTrials.gov Identifier: NCT03337841    
Other Study ID Numbers: AURORA study
First Posted: November 9, 2017    Key Record Dates
Last Update Posted: November 9, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Masatoshi Kudo, Kindai University:
Hepatocellular carcinoma
Neo adjuvant chemotherapy
Adjuvant chemotherapy
Immune checkpoint inhibitor
Pembrolizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents